Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 299227
For the Development Program, Licensee engages Licensor to perform the scope of work for Development and Commercialization of AB rated Modified Release Dosage forms of Propranolol.
Licensor grants a sole and exclusive license under the Know-How with the right to sublicense within the Territory to use the Product in the manufacture of the Finished Dosage Form, and use, offer for sale, market and sell the Finished Dosage Form provided, however, that Licensee shall not grant sublicenses in the United States without the consent of Licensor, which consent shall not be unreasonably withheld.
Licensor grants a non exclusive license to use and sublicense the right to use the Trademark.
The Active Ingredient means Propranolol HC1.
Product means a Modified Release Composition containing the Active Ingredient and certain excipients, said compositions being bioequivalent to InderalÂ® LA and produced by Licensor and meeting the Specifications.
The trademark use permitted is Produced with Eurand Trademark technology.
Propranolol is a beta-blocker. Beta-blockers affect the heart and circulation (blood flow through arteries and veins). Propranolol is used to treat tremors, angina (chest pain), hypertension (high blood pressure), heart rhythm disorders, and other heart or circulatory conditions.
Propranolol HCl is a novel bedtime-dosed, extended-release formulation of this beta blocker for the treatment of hypertension.
IPSCIO Record ID: 203528
Patent Rights means
Application Serial No. 09/554,102 Filed May 4, 2000
Application Serial No. 09/555.095 Filed May 24, 2000
IPSCIO Record ID: 172762
Licensor is the owner of original processes and know-how for the development and manufacture of encapsulated pharmaceutical substances.
IPSCIO Record ID: 279388
Licensor is the owner of original processes and know-how for the development and manufacture of extended release pharmaceutical products.
IPSCIO Record ID: 172763
Licensor is the owner of original processes and know-how for the manufacture of sustained release pharmaceutical substances.
Pancrelipase, a pancreatic enzyme used primarily by cystic fibrosis patents to aid in digestion, for the generic market.